VAC-IE Chemotherapy Protocol for Sarcoma Treatment

What Is the VAC-IE Chemotherapy Protocol?

V = Vincristine

A = Adriamycin (Doxorubicin)

C = Cyclophosphamide

I = Ifosfamide

E = Etoposide

This protocol is used as part of multidisciplinary care for high-grade sarcomas such as Ewing sarcoma, PNET (peripheral primitive neuroectodermal tumor) and sometimes bone sarcomas.

Standard treatment alternates VAC and IE cycles.

The combination aims to shrink tumors, control systemic spread and improve surgery/radiotherapy success.

Vincristine

• Class: Vinca alkaloid
• Action:  Stops cell division. By binding tubulin proteins that form microtubules, it prevents proper chromosome separation during mitosis, arresting cells in G2/M and directing them toward apoptosis.

Doxorubicin (Adriamycin)

• Class: Anthracycline antibiotic
• Action: Intercalates between DNA strands, disrupting DNA synthesis and RNA transcription. It also inhibits topoisomerase II, preventing DNA repair. These combined effects cause permanent tumor cell damage and death.

Cyclophosphamide

• Class: Alkylating agent
• Action: Converted to its active form by liver enzymes. Covalent binding to DNA guanine bases creates cross-links, preventing DNA separation and causing cell death.

Ifosfamide

• Class: Alkylating agent (a cyclophosphamide derivative)
• Action: Works similarly to cyclophosphamide. Converted into active metabolites in the liver, it creates DNA cross-links and disrupts replication and transcription. Cells cannot divide and undergo apoptosis.

Etoposide

• Class: Topoisomerase II inhibitor
• Action: Blocks topoisomerase II, which unwinds and reseals DNA. DNA repair remains incomplete and double-strand breaks form, leading to G2 arrest and apoptosis.

VAC + IE, combines different drug classes that stop cell division, cross-link DNA and disrupt repair to induce cell death through multiple pathways in aggressive tumors such as Ewing sarcoma. This synergy reduces tumor burden early and controls spread.

Indications

Primary Ewing Sarcoma (Bone or Soft Tissue):

• Neoadjuvant (Preoperative): Shrink the tumor, facilitate surgery, improve local control.
• Adjuvant (Postoperative): Eliminate residual micrometastatic disease and reduce recurrence risk.
• Curative intent, because Ewing sarcoma is aggressive but chemotherapy-sensitive.
• Combination: Generally combined with surgery and/or radiotherapy.
• Treatment begins with VAC + IE after diagnosis; the tumor shrinks, surgery is performed and remaining cycles follow.

Metastatic Ewing Sarcoma

• Systemic control: Targets the primary tumor and distant metastases (e.g., lung, bone marrow).
• Palliative and curative intent together: Treatment generally starts with curative intent at metastatic presentation, although long-term complete cure rates are limited.
• Goal: Extend survival and improve quality of life.

PNET (Peripheral Primitive Neuroectodermal Tumor)

• PNET belongs to the Ewing tumor family; treatment is the same.
• Neoadjuvant + adjuvant treatment + local RT if needed.
• Reduces tumor burden before surgery and recurrence risk afterward.
• Curative intent.

Osteosarcoma (Certain Rare Protocols)

Purpose: MAP is standard in osteosarcoma. Ifosfamide + etoposide may be added as an alternative in MAP-resistant, recurrent or progressive disease, generally for salvage or palliation. IE is not part of standard first-line treatment.

Dosing Interval

VAC Cycle

Vincristine

Dose: 1.5 mg/m² IV bolus (maximum single dose 2 mg), Day: 1

Adriamycin, Doxorubicin

Dose: 75 mg/m² IV infusion (generally single or divided doses), Day: 1

Cyclophosphamide

Dose: 1200 mg/m² IV infusion, Day: 1

IE Cycle

Ifosfamide

Dose: 1800–3000 mg/m²/day, Days: 5 consecutive days (total 9000–15000 mg/m²/cycle)

Mesna: Given concurrently or sequentially to prevent urotoxicity.

Etoposide

Dose: 100 mg/m²/day, Days: 1–5

Cycle 1 → VAC

Cycle 2 → IE

Cycle 3 → VAC

Cycle 4 → IE … alternating onward. Cycles are given every 21 days.

Estimated Total Infusion Time:

• VAC + IE is administered as two alternating components: VAC in odd-numbered cycles, IE in even-numbered cycles.
• Infusion time averages approximately 2 hours for both VAC and IE cycles.
• These times are based on clinical studies but may vary with physician preference or drug tolerance. Premedications and IV fluids (e.g., hydration) may require additional time.

Premedications

Antiemetic Protocol (Nausea-Vomiting Prevention)

Why Is It Important?

• Doxorubicin, Cyclophosphamide, Ifosfamide: High emetogenic risk
• Etoposide: Moderate emetogenic risk

Standard Antiemetic Recommendation:

• 5-HT3 antagonist (ondansetron, granisetron, palonosetron), before the cycle
• Dexamethasone (corticosteroid), for nausea control and additional antiemetic action
• NK1 inhibitor (aprepitant or fosaprepitant), may be added in high-risk patients.

Mesna (Uroprotection)

Why Is It Important?

• Ifosfamide and cyclophosphamide increase bladder toxicity risk (hemorrhagic cystitis).
• Mesna prevents ifosfamide metabolites from damaging the bladder.

Administration:

• Must be given concurrently with ifosfamide or high-dose cyclophosphamide cycles.
• May be IV or oral.
• Infused in divided doses equivalent to total ifosfamide dosing (e.g., 20% initially, 40% mid-infusion, 40% at the end).

Hydration

• Mandatory with both ifosfamide and cyclophosphamide.
• Adequate fluids and forced diuresis reduce bladder toxicity.
• A diuretic (e.g., furosemide) may be added if needed.

Hypersensitivity Precautions

• Etoposide may rarely cause infusion reactions.
• Diphenhydramine or low-dose steroids may be added if needed.
• This is not routine; used if a reaction develops.

Supportive Treatment

• Filgrastim/Pegfilgrastim (G-CSF): May start after a cycle to address severe neutropenia risk.
• PPI/H2 blocker: Added at some clinics to reduce corticosteroid-related gastritis risk.

Extravasation

Doxorubicin and Vincristine (Vesicants)

• Stop the infusion.
• Leave the cannula in place. Aspirate and try to withdraw as much drug as possible.
• An antidote may be administered before removing the cannula.
• Apply cold compresses. (For doxorubicin: 15–20 minutes, over 4–6 hours)
• Use a specific antidote: Doxorubicin: Dexrazoxane (Totect®), (recommended by ESMO & NCCN).
• Vincristine: No specific antidote, but hyaluronidase may be injected locally.
• Inform a plastic surgeon or oncology support team.

Ifosfamide, Cyclophosphamide, Etoposide (Irritants)

• Stop the infusion immediately.
• Aspirate.
• Warm compresses are generally recommended to dilate vessels and accelerate absorption.
• Hyaluronidase may be administered (at some centers).
• Major necrosis is unlikely, but the area should be monitored.

Special Clinical Considerations

Hematologic Toxicity (Neutropenia, Anemia, Thrombocytopenia)

• All agents suppress bone marrow; doxorubicin, cyclophosphamide and ifosfamide carry particularly high neutropenia risk.
• Check complete blood counts before every cycle.
• Low absolute neutrophil counts may require delay or dose reduction.
• G-CSF support (filgrastim, pegfilgrastim) is frequently used because febrile neutropenia risk is high.

Cardiotoxicity (Particularly Doxorubicin)

• Doxorubicin may cause cumulative dose-related myocardial damage.
• Perform echocardiography/ECG before treatment and during treatment if necessary.
• Particular caution above cumulative doses of 400–450 mg/m²!
• A cardioprotective agent (dexrazoxane) may be considered in at-risk patients.

Urotoxicity (Ifosfamide, Cyclophosphamide)

• Ifosfamide and cyclophosphamide may cause hemorrhagic cystitis.
• Mesna + substantial hydration are mandatory.
• Stop treatment and obtain urological support if hematuria develops.

Neurotoxicity (Vincristine, Ifosfamide)

• Vincristine may cause peripheral neuropathy, bowel paralysis and cranial nerve palsies.
• Ifosfamide may rarely cause encephalopathy (confusion, somnolence).
• Closely monitor neurological findings; methylene blue may be used for ifosfamide encephalopathy.

Gastrointestinal Toxicity (Mucositis, Nausea, Vomiting)

• Doxorubicin, ifosfamide and cyclophosphamide are highly emetogenic.
• A potent antiemetic protocol (5-HT3 antagonist, steroid ± NK1 inhibitor) is required.
• Oral hygiene reduces mucositis risk.

Extravasation Risk

• Doxorubicin and vincristine are vesicants. Check the venous line during infusion.
• Have dexrazoxane (Totect) and a cold/warm compress plan ready for extravasation.

Renal and Hepatic Monitoring

• Ifosfamide and cyclophosphamide are renally eliminated; monitor kidney function regularly.
• Doxorubicin is metabolized in the liver; monitor liver function and adjust doses in hepatic impairment if needed.

Fertility and Secondary Malignancy Risk

• Long-term survivors face gonadal toxicity (infertility) risk.
• Explain sperm/ovarian preservation options.
• Secondary leukemia risk from alkylating agents (particularly ifosfamide, cyclophosphamide) is rare but important.

Treatment Schedule and Multidisciplinary Monitoring

• This protocol is generally combined with surgery and radiotherapy.
• Coordinate cycle intervals carefully when planning surgery/radiotherapy.
• Regularly assess performance status, nutrition and hydration.

Adverse Effects

• Neutropenia: 85–95%
• Anemia: 70–90%
• Thrombocytopenia: 50–70%
• Nausea-vomiting: 70–90%
• Mucositis (mouth sores): 40–70%
• Infection (including febrile neutropenia): 30–50%
• Hair loss (alopecia): 90–100%
• Cardiotoxicity (cumulative doxorubicin dose-related): 5–10%
• Encephalopathy (ifosfamide-related): 10–15%
• Peripheral neuropathy (vincristine): 30–50%
• Hemorrhagic cystitis (ifosfamide/cyclophosphamide): 10–25%
• Renal dysfunction: 5–15%
• Hepatotoxicity (doxorubicin-related): 5–15%
• Infertility (long term): 20–40%
• Secondary malignancy risk (leukemia, etc., long term): <5%
• Local extravasation reactions: <5%